| 张小方,曹广海,王静.依折麦布联合辛伐他汀对慢性肾炎伴高血压患者心肾保护效果的临床研究[J].安徽医药,2016,20(8):1560-1564. |
| 依折麦布联合辛伐他汀对慢性肾炎伴高血压患者心肾保护效果的临床研究 |
| A long-term follow-up study of ezetimibe combined with simvastatin in protecting heart and kidney of patients with chronic nephritis complicated by hypertension |
| 投稿时间：2016-04-05 |
| DOI： |
| 中文关键词: 肾炎 高血压 依折麦布 辛伐他汀 治疗结果 |
| 英文关键词: Nephritis Hypertension Ezetimibe Simvastatin Treatment outcome |
| 基金项目:河南省科技攻关项目(122102310472)依折麦布联合辛伐他汀对慢性肾炎伴高血压患者心肾保护效果的临床研究张小方1,曹广海2,王静1 (1.黄淮学院,河南 驻马店 463000；2.郑州市儿童医院肾病科,河南 郑州 450000)依折麦布联合辛伐他汀对慢性肾炎伴高血压患者心肾保护效果的临床研究 张小方,曹广海,王静 A long-term follow-up study of ezetimibe combined with simvastatin in protecting heart and kidney of patients with chronic nephritis complicated by hypertension ZHANG Xiaofang,CAO Guanghai,WANG Jing |
|
| 摘要点击次数: 2782 |
| 全文下载次数: 176 |
| 中文摘要: |
| 目的 探讨依折麦布联合辛伐他汀对慢性肾炎伴高血压患者心肾保护效果。方法 选取慢性肾炎伴高血压患者68例,采用随机数字表法将患者分为对照组和观察组,各34例,剔除脱落病例,观察组最终纳入27例,对照组最终纳入24例。对照组给予辛伐他汀20 mg·d-1口服,观察组给予辛伐他汀20 mg·d-1+依折麦布10 mg·d-1口服,持续用药12周。随访至2015年4月,平均随访48个月,观察治疗前、治疗12周、随访末期血脂、血管内皮功能、心肾功能指标,记录低密度脂蛋白胆固醇(LDL-C)达标率、临床终点事件发生率。结果 观察组治疗12周、随访末期总胆固醇(TC)、三酰甘油(TG)、LDL-C、血清内皮素-1(EF-1)、肌酐(Scr)、24 h蛋白定量明显低于对照组,一氧化氮(NO)、左室射血分数(LVEF)明显高于对照组(P＜0.05)；观察组治疗后12周、随访末期LDL-C达标率为85.19%、74.07%均明显高于对照组的58.33%、41.67%(P＜0.05)；观察组临床终点事件发生率较对照组降低11%,但两组组间对比差异无统计学意义(P＞0.05)。结论 依折麦布联合辛伐他汀治疗慢性肾炎伴高血压降脂效果明显,可提高LDL-C控制率,改善血管内皮细胞,保护心肾功能。 |
| 英文摘要: |
| Objective To investigate the effects of ezetimibe combined with simvastatin in protecting heart and kidney of patients with chronic nephritis complicated by hypertension.Methods Sixty-eight cases of patients with chronic nephritis complicated by hypertension were selected and assigned into control group and observation group by random number table method,34 cases in each group.Excluding off cases,there finally were 27 cases in the observation group and 24 cases in the control group.The control group was treated with oral administration of simvastatin 20 mg·d-1,while the observation group was treated with oral administration of simvastatin 20 mg·d-1 combined with ezetimibe 10 mg·d-1.The medication lasted for 12 weeks.The patients were followed up till April 2015,and the average length of follow-up was 48 months.The blood lipid,vascular endothelial function,cardiac and renal function indexes were observed before treatment,12 weeks after treatment and at the end of follow-up.The control rate of low-density lipoprotein (LDL-C) and incidence of clinical outcome events were recorded.Results Twelve weeks after treatment and at the end of follow-up,total cholesterol (TC),triglyceride (TG),LDL-C,endothelin 1 (ET-1),serum creatinine (Scr) and 24h protein quantification in the observation group were significantly lower than those in the control group while nitric oxide (NO) and left ventricular ejection fraction (LVEF) were significantly higher than those in the control group (P<0.05);Twelve weeks after treatment and at the end of follow-up,the control rates of LDL-C in the observation group (85.19%,74.07%) were significantly higher than those in the control group (58.33%,41.67%,P<0.05).The incidence of clinical outcome events in the observation group was lower than that in the control group without significant difference (P>0.05).Conclusions The lipid-lowering effect of ezetimibe combined with simvastatin in the treatment of chronic nephritis with hypertension is obvious.The regimen can improve the control rate of LDL-C,improve vascular endothelial cells and protect the cardiac and renal function. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
